104 completed, 8 unknown, 3 recruiting, 3 terminated. 47 Phase 3, 34 Phase 2, 14 Phase 4, 12 Phase 1, 8 Not applicable.
Follow Heptavalent Pneumococcal Conjugate Vaccine: new trials by email Literature Review of Heptavalent Pneumococcal Conjugate Vaccine trials Research Report on Heptavalent Pneumococcal Conjugate Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease | Phase 2 | Recruiting | Sinovac Life Sciences Co., Ltd. | 420 | 2025-11-25 | 2025-12-24 |
| Clinical Trial of PCV24 in Infants Aged 2-23 Months Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease | Phase 1 | Recruiting | Sinovac Life Sciences Co., Ltd. | 180 | 2025-05-08 | 2026-01-28 |
| Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Sinovac PCV13, Prevnar® - Pneumococcal Infectious Disease | Phase 3 | Recruiting | Sinovac Life Sciences Co., Ltd. | 3080 | 2024-10-23 | 2026-01-28 |
| Study of Gamma PN3 in the Elderly Gamma PN3, Prevnar - Pneumonia, Pneumococcal | Phase 1 | Completed | GPN Vaccines | 105 | 2024-08-26 | 2025-05-11 |
| PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) PPV23, PCV13, Saline for injection - Streptococcus Pneumonia | Phase 4 | Unknown | Liverpool School of Tropical Medicine | 516 | 2021-07-28 | 2023-01-05 |
| Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infections, Streptococcal Infections | Phase 3 | Completed | CanSino Biologics Inc. | 3420 | 2021-04-13 | 2024-04-02 |
| Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy PCV13, PPV23, Rituximab - Invasive Pneumococcal Infection | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2018-02-05 | 2025-11-20 |
| Pneumococcal Vaccines in Patients With Asthma PCV13, PPSV23 - Asthma | Phase 4 | Completed | Mayo Clinic | 17 | 2017-10-01 | 2021-11-05 |
| Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old) 7-valent pneumococcal conjugate vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine - Diseases Caused by Streptococcus Pneumoniae Serotypes | Phase 3 | Completed | Walvax Biotechnology Co., Ltd. | 2760 | 2016-04-08 | 2020-10-14 |
| Baby Vaccine Study (Sched3) DTaP/IPV/Hib vaccine, 13 valent Pneumococcal Conjugate Vaccine, Rotavirus vaccine - Infectious Diseases | Phase 2 | Completed | University of Oxford | 189 | 2015-08-01 | 2021-09-20 |
| Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses PCV-13, PPSV-23 - HIV, Pneumococcal Infections | Not applicable | Unknown | University of Colorado, Denver | 60 | 2014-08-01 | 2020-11-18 |
| Systems Biology of PNEUMOVAX®23 and PREVNAR 13® PNEUMOVAX, Prevnar - Pneumococcal Infection | Not applicable | Completed | Emory University | 88 | 2014-04-01 | 2018-10-02 |
| Prevenar (13v) Infant Drug Use Investigation Prevenar (13v) - Infants | Completed | Pfizer | 1087 | 2014-03-01 | 2017-06-19 | |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 558 | 2013-10-01 | 2016-01-05 |
| Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant PCV 13 - Multiple Myeloma | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 8 | 2013-02-01 | 2017-02-02 |
| A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China 7-valent Pneumococcal Conjugate Vaccine, 13-valent Pnumococcal Conjugate vaccine - Pneumococcal Infection | Phase 3 | Completed | Pfizer | 1674 | 2012-09-01 | 2026-06-02 |
| PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae PCV7 (Pneumococcal 7-Valent Conjugate Vaccine), Hib Vaccine - Streptococcal Pneumonia, Nasopharyngeal Diseases | Not applicable | Completed | Centers for Disease Control and Prevention, China | 3281 | 2012-06-01 | 2016-05-20 |
| Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1106 | 2011-09-01 | 2014-07-16 |
| Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Placebo - Dengue, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 720 | 2011-07-18 | 2022-03-25 |
| Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide) - Myeloma | Phase 2 | Completed | University of Pennsylvania | 28 | 2011-05-10 | 2020-04-06 |
Showing 20 of 118. Sign in to see all of them.
Pneumococcal Infections (31) · Haemophilus Infections (14) · Meningococcal Infections (12) · Pneumonia (10) · Diphtheria (8) · Poliomyelitis (8) · Hepatitis B (7) · Streptococcal Infections (7) · Tetanus (7) · Whooping Cough (7) · Meningitis (6) · HIV Infections (5) · Measles (5) · Meningitis, Meningococcal (4) · Mumps (4)
GlaxoSmithKline (22) · Wyeth is now a wholly owned subsidiary of Pfizer (19) · Novartis Vaccines (8) · Pfizer (8) · Sanofi Pasteur, a Sanofi Company (8) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Sinovac Life Sciences Co., Ltd. (3) · Assistance Publique - Hôpitaux de Paris (2) · Merck Sharp & Dohme LLC (2) · The Hospital for Sick Children (2) · University of Oxford (2) · Abramson Cancer Center at Penn Medicine (1) · CHU de Quebec-Universite Laval (1) · CIHR Canadian HIV Trials Network (1) · CanSino Biologics Inc. (1)
United States (29) · United Kingdom (8) · Canada (7) · China (7) · Spain (7) · France (6) · Germany (6) · Poland (6) · Australia (5) · Philippines (4) · Colombia (3) · Finland (3) · Italy (3) · Mexico (3) · Puerto Rico (3)
Aaron Rapoport, M.D. (1) · Adnan AL-lahham, PhD (1) · Amar Safdar, MD (1) · Ann Hermansson, MD, PhD (1) · Antonello Punturieri, MD (1) · Anu Kantele, MD PhD (1) · Avni Y Joshi (1) · Chien-Ching Hung, MD, MSc (1)
PMID 23965217, PMID 31110098, PMID 21704105, PMID 22327493, PMID 29028802, PMID 15882530, PMID 17090650, PMID 17109339, PMID 17391816, PMID 17938165, PMID 18182599, PMID 18470901, PMID 19150378, PMID 19209097, PMID 19325447, PMID 19325451, PMID 19325452, PMID 19414694, PMID 19556517, PMID 19584345, PMID 19663708, PMID 19776196, PMID 20199764, PMID 20206670, PMID 20299956, PMID 20435707, PMID 20823436, PMID 20943882, PMID 21044669, PMID 21334243, PMID 21443960, PMID 21539882, PMID 21606542, PMID 21645573, PMID 21695210, PMID 21807056, PMID 21813135, PMID 22094635, PMID 22123890, PMID 22198517, PMID 22318278, PMID 22652582, PMID 22693229, PMID 23011012, PMID 23324563, PMID 23451070, PMID 23535358, PMID 23566945, PMID 23786774, PMID 23804191
2009 (2), 2004 (1), 2008 (1), 2014 (1), 2016 (1), P30CA006973 (1), R01AI108479 (1), U10HL074424 (1), U19AI090023 (1)